文献速递焦虑、强迫与应激相关障碍物质与行为成瘾

Project Harmony:共病PTSD与物质使用障碍行为及药物试验的个体患者数据Meta分析

Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders.
PubMed 文献 · Am J Psychiatry · 2022-12-07

该研究系统检索截至2020年12月的36项试验(N=4,046),采用个体患者数据Meta分析与倾向评分加权多水平模型,比较多种行为与药物治疗对共病PTSD及酒精或药物使用障碍成人的效果。结果显示,与常规治疗相比,聚焦创伤治疗联合物质使用障碍药物治疗在治疗结束时对PTSD严重度(d=-0.92)和酒精使用严重度(d=-1.10)的 comparative 效应量最大。

要点

  • 聚焦创伤治疗联合物质使用障碍药物治疗对PTSD和酒精使用严重度改善最大。
  • 酒精或药物使用障碍药物治疗、聚焦创伤整合与非整合治疗也显示较大效应量。
  • 几乎所有治疗均观察到PTSD症状和酒精使用的下降。

核心结论

  • 多种方法可有效治疗共病PTSD与物质使用障碍,酒精靶向药物联合聚焦创伤行为治疗可带来早期且持续的改善。

研究设计与样本

  • 系统检索PsycINFO、MEDLINE和ClinicalTrials.gov截至2020年12月的36项试验,共4,046名成人,采用个体患者数据Meta分析、调节非线性因子分析和倾向评分加权多水平模型。

主要发现

  • 与常规治疗相比,聚焦创伤治疗联合物质使用障碍药物治疗在治疗结束时对PTSD严重度的比较效应量为d=-0.92(95%CI=-1.57, -0.30)。
  • 同一联合治疗在治疗结束时对酒精使用严重度的比较效应量为d=-1.10(95%CI=-1.54, -0.68)。
  • 酒精或药物使用障碍药物治疗、聚焦创伤整合治疗和聚焦创伤非整合治疗也显示较大的比较效应量。
  • 几乎所有治疗均观察到PTSD症状和酒精使用的下降。

临床怎么用

  • 临床可考虑将酒精靶向药物与聚焦创伤行为治疗联合使用,以早期且持续改善共病PTSD与酒精使用严重度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treatment efficacy for co-occurring posttraumatic stress disorder (PTSD) and substance use disorders is well established, yet direct evidence for comparative effectiveness across treatments is lacking. The present study compared the effectiveness of several behavioral and pharmacological therapies for adults with co-occurring PTSD and alcohol or other drug use disorders. METHODS: A systematic search of PsycINFO, MEDLINE, and ClinicalTrials.gov was conducted through December 2020 for trials targeting PTSD, alcohol or other drug use disorders, or both disorders (36 studies, N=4,046). Primary outcomes were severity scores for PTSD, alcohol use, and drug use, estimated via moderated nonlinear factor analysis. Propensity score weight-adjusted multilevel models were used. Model-predicted effect sizes were estimated for each treatment, and comparative effect sizes for each active arm against treatment as usual, at end of treatment and at 12-month follow-up. RESULTS: Compared with treatment as usual, combining trauma-focused therapy and pharmacotherapy for substance use disorders showed the largest comparative effect sizes for PTSD severity (d=-0.92, 95% CI=-1.57, -0.30) and alcohol use severity (d=-1.10, 95% CI=-1.54, -0.68) at end of treatment. Other treatments with large comparative effect sizes included pharmacotherapies for alcohol or other drug use disorders, trauma-focused integrated therapies, and trauma-focused nonintegrated therapies. Reductions in outcomes for PTSD symptoms and alcohol use were observed for nearly all treatments. CONCLUSIONS: The findings provide support for treating comorbid PTSD and substance use disorders using a variety of approaches, with alcohol-targeted pharmacotherapies and trauma-focused behavioral therapies as a combination of treatments that lead to early and sustained improvements in PTSD and alcohol use severity. Further treatment development is indicated for combining behavioral and pharmacological treatments for synergized impact and understanding the mechanisms of action and conditions under which each treatment type is optimized.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hien DA, Morgan-López AA, Saavedra LM, et al. Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders. Am J Psychiatry. 2022. PMID: 36475373. doi:10.1176/appi.ajp.22010071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。